Amazon Clears Out Dell Inspiron (Ryzen 7, 1TB SSD, Win 11 Pro) Stock, Now $2,800 Off and Bonuses Included
Amazon currently has for sale a rare deal about a fantastic Windows laptop. There's a Dell Inspiron 16-inch (touchscreen) laptop featuring an AMD Ryzen 7 processor, 32GB DDR5 RAM and a massive 1TB SSD which is priced at $999, which represents a whopping 71% discount off its normal price of $3,399.
To make this deal even less resistible, Amazon is throwing in $399 worth of extras: Windows 11 Pro, a one-time lifetime subscription to Microsoft Office, an external optical DVD drive and a wireless mouse. When you subtract the value of these extras from the cost of the laptop itself, you get down to around $600 so you're talking an astonishing $2,800 in savings.
See at Amazon
Dell Is a Safe Choice
Under the hood, this Dell Inspiron laptop is powered by the AMD Ryzen 7 8840U processor, an eight-core, sixteen-thread powerhouse that makes multi-tasking super smooth. Whether you're editing large files, running complex software or juggling multiple tabs, this processor ensures responsive performance. Paired with 32GB of DDR5 RAM (well beyond what the average user will ever require) this notebook is ready for anything from content creation and data analysis.
The 16-inch FHD touchscreen display is another winner in this machine: It offers sharp rich images and extremely responsive touch functionality which makes it perfect for everything from high-precision design work to watching movies. ComfortView Plus technology reduces eye strain due to damaging blue light so that you can work or relax for hours without a hitch.
With a 1TB PCIe SSD, you'll enjoy lightning-fast boot times, quick file access and plenty of space for your documents,. The SSD not only speeds up everyday tasks but also makes the laptop more reliable and durable compared to traditional hard drives. A number of connectivity options including USB 3.2 Gen 1 and Gen 2 Type-C ports, HDMI, and SD card reader enable you to hook up all your accessories and devices without the hassle.
Last but not least, the Inspiron 16 is packed with utilities to keep you productive: Its 1080p FHD webcam and dual-array microphones deliver clear communication on video calls and a battery life that lasts all day means work or class without searching for an electrical outlet. That makes the Inspiron 16 a good value for anyone who needs reliability, flexibility, and performance in a small package.
The Dell Inspiron 16 touchscreen laptop is one of the best deals you'll find anywhere, make sur you don't miss it.
See at Amazon
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Is Opendoor Stock a Buy at New 52-Week Highs?
Once a penny stock struggling to keep its head above water, online home flipper Opendoor Technologies (OPEN) is staging an astounding comeback. The company's shares have exploded more than 430% in just one month, transforming OPEN stock from a Wall Street underdog into one of the hottest names on the tape. The meteoric rise gained ferocious momentum starting on July 14, when EMJ Capital founder Eric Jackson disclosed a new position in OPEN. Jackson called the stock a potential '100-bagger' and projected the company would post its first positive EBITDA as early as next month. The vote of confidence set the spark, but what followed was an outright blaze. More News from Barchart Nvidia Stock Warning: This NVDA Challenger Just Scored a Major Customer Dear QuantumScape Stock Fans, Mark Your Calendars for July 23 Should You Buy the Post-Earnings Dip in Lockheed Martin Stock? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Opendoor rallied 15% the day that Jackson posted his remarks and shares never looked back. Daily double-digit surges followed, culminating in a fresh 52-week high of $4.97 on July 21. At one point that day, OPEN stock skyrocketed as much as 115% intraday before triggering a Nasdaq volatility halt. As the dust settles, investor eyes are fixed on what comes next. About Opendoor Stock Opendoor operates as a full-stack iBuyer. With a market capitalization of $2.3 billion, its core business revolves around purchasing homes directly from sellers, carrying out necessary upgrades, and selling them at a premium. The company also runs an integrated ecosystem that includes a digital marketplace and agent services to support the buying and selling experience. Over the last 52 weeks, OPEN stock has delivered a respectable 14% return. However, that performance pales in comparison to what has unfolded in recent months. In the last six months alone, the stock has surged 105%. In just the past three months, shares have skyrocketed roughly 190%. Opendoor Surpasses Q1 Earnings On May 6, Opendoor released its fiscal 2025 first-quarter results, handing Wall Street an earnings report that outperformed expectations. Although revenue dropped 2.4% year-over-year (YOY) to $1.15 billion, the company still beat the consensus estimate of $1.06 billion. Yet in Opendoor's business model, revenue alone tells only part of the story. The company can generate revenue by flipping homes, regardless of whether it books a profit, which is why analysts tend to focus more on profitability and cash flow. On that front, the company made notable strides. Adjusted net loss narrowed 21% to $63 million, with net loss per share narrowing 25% to $0.12. This came in better than analyst projections. More importantly, adjusted EBITDA loss was reduced to $30 million from $50 million a year earlier, signaling operational improvements. Despite weak buyer demand, management offered forward guidance that struck a cautiously optimistic tone. The company expects adjusted EBITDA in Q2 to swing into positive territory, between $10 million and $20 million. Meanwhile, 3,609 homes were acquired during Q1, up 4% YOY as the company geared up for peak buying season. Opendoor currently holds $559 million in cash on its balance sheet, which provides a runway to manage near-term operations. However, it cannot afford to keep losing money indefinitely. The company is slated to report Q2 earnings on Aug. 5, and is projecting revenue between $1.45 billion and $1.53 billion along with contribution profit of $65 million to $75 million. Meanwhile, analysts expect Q2 loss per share to narrow 56% YOY to $0.04. For full-year fiscal 2025, the loss per share is expected to reduce by 55% to $0.24 and further tighten by 4.2% to $0.23 in the next fiscal year. What Do Analysts Expect for Opendoor Stock? Eric Jackson's bullish bet has undeniably put Opendoor back in the spotlight. Jackson outlined a price target of $82, calling OPEN a multi-year compounding opportunity. While this projection has energized retail traders, the broader analyst community remains skeptical. Opendoor still grapples with profitability issues, and its balance sheet shows significant debt obligations. That limits flexibility and increases vulnerability to macroeconomic pressures. Currently, the consensus rating on OPEN stock is 'Hold.' Among the 10 analysts with coverage, only one has a 'Strong Buy" rating while seven recommend to 'Hold.' One analyst rates the stock a 'Moderate Sell," while another rates it a 'Strong Sell.' The average price target is set at $1.14, well below the current market price. In fact, shares now trade above the Street-high price target of $2 as well. Amid intense market euphoria and tempered analyst caution, OPEN stock's sharp rally may warrant patience over pursuit at these elevated levels. On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
ISRG: Solid Numbers, Tariff Concerns
Key Points Intuitive Surgical posted a strong quarter, topping expectations on 20%-plus revenue and earnings growth. The company's latest-generation systems are continuing to gain traction. Intuitive sounded a cautious outlook about the quarters ahead due to tariff uncertainty. 10 stocks we like better than Intuitive Surgical › Here's our initial take on Intuitive Surgical's (NASDAQ: ISRG) financial report. Key Metrics Metric Q2 2024 Q2 2025 Change vs. Expectations Revenue $2.01 billion $2.44 billion 20% Beat Adjusted EPS $1.78 $2.19 23% Beat Da Vinci systems placed 341 395 16% n/a Da Vinci total installed systems 9,203 10,488 14% n/a Intuitive Momentum Remains Strong Robotic surgery pioneer Intuitive Surgical posted another solid quarterly beat, growing revenue by 20% and earnings per share by 23% in the most recent quarter. The company continues to see strong demand for its machines and strong usage once they are installed, driving a beat. The company placed 395 of its da Vinci systems in the quarter, up 16% from a year ago, and the number of high-end da Vinci 5 systems more than doubled to 180. At the end of the quarter, Intuitive had an installed base of 10,488 systems, up from 9,203 a year ago. Worldwide procedures grew by 17%, a good sign for a company that sells not just the new systems but disposable equipment needed on a per-surgery basis. The company ended the second quarter of 2025 with $9.53 billion in cash, up $431 million during the quarter, driven by cash generated from operations. Immediate Market Reaction Though the quarter was strong, there are some questions about how tariffs would impact the company in the quarters ahead. Intuitive share prices were down about 4% in after-market trading following the release but ahead of the company's call with investors. What to Watch Intuitive does not expect that 17% procedure growth to sustain into the second half. For the full year, the company forecasts procedure growth of about 15.5% to 17%, compared to 17% in the quarter and all of last year. Operating expenses are also expected to climb by 10% to 14% for the year, compared to 10% in 2024. Intuitive said the updated expectation "reflects the company's estimates of the adverse impact from tariffs that are currently in effect as of the time of this press release and assumes such tariffs remain in place." The company continues to push the envelope, during the quarter conducting a telesurgery demonstration in which doctors in Georgia and France operated a dual-console da Vinci 5 system to simulate a procedure. Those sorts of innovations promise to both allow more patients to benefit from the systems and open up new potential markets for the company. Intuitive remains on the path for growth, but near-term tariff headwinds are likely to continue to cloud the picture in the quarters to come. Helpful Resources Full earnings report Investor relations page Additional coverage Should you invest $1,000 in Intuitive Surgical right now? Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $641,800!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,023,813!* Now, it's worth noting Stock Advisor's total average return is 1,034% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool has a disclosure policy. ISRG: Solid Numbers, Tariff Concerns was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med
Winter Park, Florida--(Newsfile Corp. - July 23, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized wellness solutions, is thrilled to announce that its medical subsidiary, Adia Med, has officially filed to become an in-network provider with TRICARE, the healthcare program serving approximately 9.5 million active-duty service members, retirees, National Guard and Reserve members, and their families worldwide. This step, paired with Adia Med's anticipated approval as a United Healthcare provider by August 1, 2025, positions the company to transform healthcare access for millions. Adia Med expects to secure TRICARE in-network provider status by August 31, 2025, tapping into a program that paid out $50.6 billion for medical treatments in FY2019 to support its beneficiaries. Evaluation of the TRICARE Program: Fiscal Year 2019 Report to Congress. To view an enhanced version of this graphic, please visit: This strategic filing positions Adia Med to serve TRICARE's extensive network of beneficiaries, including military personnel and their families, by offering innovative regenerative treatments such as Umbilical Cord Blood Stem Cell (UCB-SC) therapies, Autologous Hematopoietic Stem Cell Transplantation (AHSCT), and Therapeutic Plasma Exchange (TPE). These therapies, provided at Adia Med's Winter Park clinic and planned satellite locations, target conditions like Multiple Sclerosis, joint pain, torn tendons, and other orthopedic and wellness needs, aligning with Adia Nutrition's mission to revolutionize healthcare accessibility. "We're fired up to support the 9.5 million TRICARE beneficiaries, including our nation's military heroes and their families, by bringing our regenerative therapies into their reach," said Larry Powalisz, CEO of Adia Nutrition Inc. "With TRICARE's massive $50.6 billion investment in medical care, our filing to join their network, alongside our imminent United Healthcare approval, will make advanced treatments more accessible and affordable, driving transformative health outcomes and fueling Adia Med's growth." The TRICARE filing complements Adia Med's recent progress with United Healthcare, where the company has already begun submitting its first patient insurance claims, signaling near-final integration. By securing in-network status with both TRICARE and United Healthcare, Adia Med will join an elite group of providers meeting rigorous standards for clinical excellence, compliance, and patient care. These partnerships will enable insurance reimbursement for Adia Med, enhancing affordability and accessibility for patients seeking innovative treatments. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
